These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23625215)

  • 1. Prevalence of amino acid changes in the yvqF, vraSR, graSR, and tcaRAB genes from vancomycin intermediate resistant Staphylococcus aureus.
    Yoo JI; Kim JW; Kang GS; Kim HS; Yoo JS; Lee YS
    J Microbiol; 2013 Apr; 51(2):160-5. PubMed ID: 23625215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR.
    Kato Y; Suzuki T; Ida T; Maebashi K
    J Antimicrob Chemother; 2010 Jan; 65(1):37-45. PubMed ID: 19889788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
    Cui L; Neoh HM; Shoji M; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1231-4. PubMed ID: 19124662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation.
    Park C; Shin NY; Byun JH; Shin HH; Kwon EY; Choi SM; Kim SH; Kwon JC; Park SH; Choi JH; Yoo JH; Yoo JI; Chung GT; Lee DG
    J Med Microbiol; 2012 Mar; 61(Pt 3):345-352. PubMed ID: 22016559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus.
    Doddangoudar VC; O'Donoghue MM; Chong EY; Tsang DN; Boost MV
    J Antimicrob Chemother; 2012 Sep; 67(9):2101-6. PubMed ID: 22643192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
    BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
    Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
    Gardete S; Kim C; Hartmann BM; Mwangi M; Roux CM; Dunman PM; Chambers HF; Tomasz A
    PLoS Pathog; 2012 Feb; 8(2):e1002505. PubMed ID: 22319446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of vancomycin nonsusceptible strains in clinical isolates of Staphylococcus aureus in northern Iran.
    Asadpour L; Ghazanfari N
    Int Microbiol; 2019 Dec; 22(4):411-417. PubMed ID: 30811005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.
    Hort M; Bertsche U; Nozinovic S; Dietrich A; Schrötter AS; Mildenberger L; Axtmann K; Berscheid A; Bierbaum G
    Microbiol Spectr; 2021 Oct; 9(2):e0052821. PubMed ID: 34668723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ; Lin MH; Shu JC; Lu JJ
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated Exposure of Vancomycin to Vancomycin-Susceptible Staphylococcus aureus (VSSA) Parent Emerged VISA and VRSA Strains with Enhanced Virulence Potentials.
    Nguyen A; Roy JJS; Kim JH; Yun KH; Lee W; Kim KK; Kim T; Chaurasia AK
    J Microbiol; 2024 Jul; 62(7):535-553. PubMed ID: 38814539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of vancomycin-intermediate Staphylococcus aureus among clinical isolates in Iran: A systematic review and meta-analysis.
    Baseri N; Najar-Peerayeh S; Bagheri Amiri F
    J Glob Antimicrob Resist; 2018 Dec; 15():178-187. PubMed ID: 29981455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
    Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
    J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.